Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Date:5/14/2012

1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements.  Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons, including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

 

 PALATIN TECHNOLOGIES, INC.and Subsidiary

 Consolidated Statements of Operations

(unaudited)Three Months Ended March 31,Nine Months Ended March 31,2012201120122011REVENUES:Contract$
23,996$
,294$
2,705$
472,849Grant---846,768Total revenues23,99661,29462,7051,319,617OPERATING EXPENSES:Research and development4,705,6621,722,4329,683,1127,159,634General and administrative1,344,861955,5473,473,9903,226,798Total operating expenses6,050,5232,677,97913,157,10210,386,432Loss from operations(6,026,527)(2,616,685)(13,094,397)(9,066,815)OTHER INCOME (EXPENSE):Investment income5,95518,982
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ - RepliCel Life ... regenerative medicine company focused on the development of autologous ... out of the University of Calgary in conjunction with ... Carolina, which further validates the company,s ongoing clinical research ... effects of pattern baldness. The paper entitled ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
(Date:12/22/2014)... December 22, 2014 Fertility Associates of ... Egg Bank USA , a network of more than ... this partnership, patients have fast access to a national ... fertilization, IVF . Fertility Associates of Memphis is the ... fertility treatment option. , Dr. William Kutteh , ...
(Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... talent when the key skills for today's success are ... for talent in order to compete in the global ... is a misperception that there is a shortage of ... is that there are many qualified, highly skilled, technical ...
... I started this column just over four years ago, I had ... year. My interest in writing a column was to share with ... would help them with business plans, presentations, and just overall awareness ... as a biotech CEO, I quickly realized that I couldn't afford ...
... Pharmaceuticals , a privately held pharmaceutical company based in ... 2MD, its lead osteoporosis compound. , ,The study is ... bone mineral density in postmenopausal women. Osteoporosis, a disease ... in susceptibility to fractures, occurs frequently in postmenopausal women ...
Cached Biology Technology:Getting beyond the vortex of corporate mediocrity 2Getting beyond the vortex of corporate mediocrity 3Getting beyond the vortex of corporate mediocrity 4A Midwest life-science odyssey comes full circle 2A Midwest life-science odyssey comes full circle 3A Midwest life-science odyssey comes full circle 4A Midwest life-science odyssey comes full circle 5A Midwest life-science odyssey comes full circle 6A Midwest life-science odyssey comes full circle 7A Midwest life-science odyssey comes full circle 8
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... crooked beady eyes peeking out of a the shell do ... murky waters of the Chesapeake Bay. They also produce important ... from an adolescent into a full-fledged adult. Scientists at the ... a new hormone in those eyestalks responsible for forming body ...
... creatures whose state of mind can usually be observed ... proposed by Dr Paul Ekman, posits there are six ... through specific facial expressions, regardless of language or culture. ... New research published in the journal Current ...
... become abundant, threaten species richness and the well-functioning of ... that attempt to restrict the expansion of non-native species ... invasions are a serious environmental problem. An example of ... world is Fallopia japonica , the ...
Cached Biology News:Hormone in crab eyes makes it possible for females to mate and care for their young 2Written all over your face: Humans express 4 basic emotions rather than 6 2Written all over your face: Humans express 4 basic emotions rather than 6 3Are invasive plants a problem in Europe? Controversial views among invasion biologists 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (E6027) or contact customer s...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
... HPLC range has now been ... a quaternary low pressure mixing ... pressure mixing pump. These ... add even more versatility to ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
Biology Products: